



Release No 334

09 April 2008

**Share Buyback in H. Lundbeck A/S**

Acting on its authorization to acquire up to 10% of its shares, Lundbeck's Supervisory Board has resolved to initiate a share buyback program. Under the program Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005. The buyback program is expected to be completed by the end of 2008.

During any one single trading day a maximum of 25% of the average daily trading volume of Lundbeck shares on OMX Nordic Exchange Copenhagen, calculated over 20 days prior to each trading date, will be bought back, as the share buyback program is implemented in accordance with the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003.

At least once every seven trading days, Lundbeck will issue an announcement in respect of the transactions made under the program.

The following transactions have been made under the program:

	No. of shares	Average purchase price (DKK)	Transaction value (DKK)
Accumulated, last announcement	29,357,062	133.8955	3,930,779,391
1 April 2008	134,300	117.4987	15,780,078.10
2 April 2008	--	--	--
3 April 2008	33,574	117.5588	3,946,917.47
4 April 2008	25,200	117.5588	2,962,480.52
7 April 2008	--	--	--
8 April 2008	--	--	--
9 April 2008	--	--	--
Accumulated under the program	29,550,136	133.7885	3,953,468,867



Following the above buyback it is hereby announced that Lundbeck owns a total of 10,393,349 own shares at a nominal value of DKK 5, equal to 5.01% of the total number of 207,279,631 shares.

### **Lundbeck contacts**

*Investors:*

Jacob Tolstrup  
Director  
+45 36 43 30 79

Palle Holm Olesen  
Head of Investor Relations  
+45 36 43 24 26

*Media:*

Anders Schroll  
Head of Communication  
+45 36 43 20 81

Stock Exchange Release No 334 – 09 April 2008

### **About Lundbeck**

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.5 billion or USD 2.0 billion). The number of employees is approximately 5,300 globally. For further information, please visit [www.lundbeck.com](http://www.lundbeck.com)